NRX — Nurexone Biologic Share News
0.000.00%
Last trade - 00:00- CA$51.09m
- CA$49.75m
Brief: NurExone Announces Private Placement
Brief: NurExone Biologic Announces Advancements In Extracellular Vesicles Functionality With Enhanced Potency And Cellular Uptake For Potentially Better Drug Delivery
Brief: Nurexone And Particle Metrix Announce Collaboration In Extracellular Vesicles Analysis Using State-Of-The-Art Analytic Device
Brief: Nurexone Reports Q1 2023 Financial Results, Provides Corporate Update
Brief: NurExone Granted U.S. Patent For Technology And Drug Composition Of Exo-Pten, Designed For Treating Acute Spinal Cord Injuries
Brief: Nurexone Biologic Reports Additional Positive Preclinical Trial Outcomes With Exopten 75% Of Paralyzed Rats Show Recovery After Acute Spinal Cord Injury Study
Brief: Nurexone Biologic is Developing Exopten
Brief: Medigus Says Polyrizon Signed Deal With Nurexone
Brief: Walmer Capital says transaction with Renex terminated
Brief: Walmer Capital Corp provides corporate update